
News|Articles|October 9, 2012
FDA approves cysteamine ophthalmic solution 0.44% for treatment of corneal cystine crystals in cystinosis patients
FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44%, a topical ophthalmic therapeutic, developed in partnership with the National Institutes of Health (NIH), for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
4 things to know about the Abarca/LucyRx merger
2
Healthcare's AI push is creating a new workforce challenge
3
EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes
4
FDA expands Capvaxive indication to include adolescent patients at risk for pneumococcal disease
5

































